The tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option. The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19?
Cortegiani, A., Ippolito, M., Ingoglia, G., & Einav, S. (2020). Chloroquine for COVID-19: rationale, facts, hopes. CRITICAL CARE, 24(1) [10.1186/s13054-020-02932-4].
Data di pubblicazione: | 2020 | |
Titolo: | Chloroquine for COVID-19: rationale, facts, hopes | |
Autori: | ||
Citazione: | Cortegiani, A., Ippolito, M., Ingoglia, G., & Einav, S. (2020). Chloroquine for COVID-19: rationale, facts, hopes. CRITICAL CARE, 24(1) [10.1186/s13054-020-02932-4]. | |
Rivista: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1186/s13054-020-02932-4 | |
Abstract: | The tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option. The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19? | |
Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
s13054-020-02932-4.pdf | Versione Editoriale | Open Access Visualizza/Apri |